Publications

Filters (1)
April 3, 2019

Molecular screening of patients with FGFR alterations for a phase 1 (Ph1) study with the selective FGFR inhibitor (FGFRi) Debio…

Read more
January 23, 2018

Safety and efficacy of the selective FGFR inhibitor Debio 1347 in phase 1 study patients with fgfr genomically activated advanced…

Read more
April 21, 2016

FGFR selective inhibitor Debio1347 induces tumor regressions in FGFR2-altered gastric cancer PDX models

Read more
April 15, 2015

Mechanism of oncogenic signal activation by the novel fusion kinase FGFR3-BAIAP2L1

Read more
April 15, 2015

Characterization of Two Novel Oncogenic FGFR2 Fusions Sensitive to the FGFR Selective Inhibitor Debio 1347 in Cholangiocarcinoma

Read more
June 1, 2014

First-in-human phase I “basket” study of Debio1347 (CH5183284), a novel FGFR inhibitor, in patients with FGFR genomically activated advanced solid…

Read more
April 7, 2014

Design and preclinical profile of CH5183284/Debio 1347, a novel orally available and selective FGFR inhibitor acting on a gatekeeper mutant…

Read more
April 7, 2014

Inhibition of FGFR3-BAIAP2L1 fusion kinase oncogenic potential by CH5183284/Debio 1347, a compound that inhibits FGFR3 kinase activity constitutively activated by…

Read more
April 7, 2014

FGFR genetic alterations as a potential predictor of the sensitivity to CH5183284/Debio 1347, a selective FGFR inhibitor with a novel…

Read more